Pfizer Inc
PFE.N- Latest Trade
- trading lower40.66USD
- -0.15
- 0.37%
- As of Mar 22 2023. Values delayed up to 15 minutes
- Today's Range
- 40.32 - 40.90
- 52 Week Range
- 39.23 - 56.32
- Previous Close
- 40.81
- Open
- 40.81
- Volume
- 4,879,802.00
- 3 Month Average Trading Volume
- 456.76
- Shares Out (Mil)
- 5,644.40
- Market Cap
- 230,348.10
- Forward P/E
- 11.73
- Dividend Yield
- 4.02
Key Statistics
2.46 mean rating - 26 analysts
- P/E Excl. Extra Items (TTM)
- 7.46
- Price To Sales (TTM)
- 2.30
- Price To Book (Quarterly)
- 2.40
- Price To Cash Flow (Per Share TTM)
- 6.32
- Total Debt/Total Equity (Quarterly)
- 37.45
- Long Term Debt/Equity (Quarterly)
- 34.38
- Return On Investment (TTM)
- 21.41
- Return On Equity (TTM)
- 16.58
2021 (millions USD)
About Pfizer Inc (PFE.N)
Company Information
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
Address
66 HUDSON BOULEVARD EASTNEW YORK, NY
10001-2192
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Albert Bourla
- Chairman of the Board, Chief Executive Officer
- David M. Denton
- Executive Vice President, Chief Financial Officer
- Angela Hwang
- Chief Commercial Officer, President, Global Biopharmaceuticals Group
- Payal Sahni
- Executive Vice President, Chief People Experience Officer
- Lidia Fonseca
- Executive Vice President, Chief Digital and Technology Officer
- Rady A. Johnson
- Executive Vice President, Chief Compliance, Quality and Risk Officer
- Douglas M. Lankler
- Executive Vice President, General Counsel
- Aamir Malik
- Executive Vice President, Chief Business Innovation Officer
- Michael Mcdermott
- Executive Vice President, Chief Global Supply Officer
- William Pao
- Executive Vice President, Chief Development Officer,
- Sally Susman
- Executive Vice President, Chief Corporate Affairs Officer
- Mikael G. Dolsten
- Chief Scientific Officer, President - Worldwide Research, Development and Medical
- Shantanu Narayen
- Lead Independent Director
- Ronald E. Blaylock
- Independent Director
- Susan Desmond-Hellmann
- Independent Director
- Joseph J. Echevarria
- Independent Director
- Scott Gottlieb
- Independent Director
- Helen H. Hobbs
- Independent Director
- Susan J. Hockfield
- Independent Director
- Dan R. Littman
- Independent Director
- Suzanne Nora Johnson
- Independent Director
- James R. Quincey
- Independent Director
- James Clifton Smith
- Independent Director
Latest News
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,938.00 | -- |
| Copper | 763.20 | 0.10% |
| Brent Crude Oil | 74.95 | 0.49% |
| CBOT Soybeans | 1,464.25 | 0.19% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,002.87 | 1.30% |
| Euro STOXX 50 | 4,181.60 | -- |
| FTSE 100 | 7,536.22 | 1.79% |
| Nikkei 225 | 27,506.26 | 2.08% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes